Advertisement
ABBV or INCY or IONS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Incyte (INCY) vs. Ionis Pharmaceuticals (IONS) Stock Comparison
Key Takeaways
- ABBV offers stability with a 3% dividend yield and $402B market cap, showing modest YTD flat performance amid strong immunology sales.
- INCY delivered 28% Q4 revenue growth from oncology drugs like Jakafi, but shares dipped post-earnings with YTD -2% return.
- IONS boasts 126% 1-year gains driven by RNA-targeted therapies, though recent months saw volatility with YTD -5%.
- All three biopharma stocks face sector headwinds but benefit from pipeline catalysts; ABBV leads in valuation support via dividends.
- Recent momentum favors IONS on rare disease approvals, while INCY shows revenue upside potential.
- Relative performance highlights trade-offs: stability in ABBV, growth in INCY and IONS.
Introduction
This stock comparison examines ABBV, INCY, and IONS, three biopharmaceutical companies navigating oncology, immunology, and rare disease markets. Investors seeking diversified exposure to healthcare growth drivers, from established blockbusters to innovative RNA therapies, will find value in understanding their relative performance, valuations, and catalysts. Amid recent market volatility, these stocks highlight contrasts in stability, momentum, and pipeline potential, aiding decisions on sector positioning and relative performance in the current environment.
ABBV Overview and Recent Performance
AbbVie (ABBV), a research-based biopharmaceutical giant, focuses on immunology, oncology, neuroscience, and aesthetics, with key products like Skyrizi, Rinvoq, and Botox driving revenue. In recent market activity, ABBV shares traded around $228, with a market cap exceeding $400B and a forward P/E of 15.7, supported by a 3% dividend yield. Sentiment has been bolstered by promising clinical results for pipeline candidates and strong growth forecasts, though competitive pressures on Skyrizi have tempered gains. Year-to-date performance remains roughly flat, reflecting resilience amid broader sector rotations, influenced by consistent earnings beats and analyst targets near $249.
INCY Overview and Recent Performance
Incyte (INCY), a biopharmaceutical firm specializing in oncology and inflammation, relies on Jakafi and expanding products like Opzelura and Zynyz. Recent weeks saw shares around $96, with a $19B market cap, following Q4 revenue of $1.51B (up 28% YoY) but an EPS miss that pressured performance. European approval for Zynyz and double-digit revenue growth have supported optimism, yet YTD returns lag at -2% amid post-earnings declines. Momentum stems from robust cash flows and pipeline progress, positioning INCY for 10-13% 2026 revenue growth, though patent risks on Jakafi influence sentiment.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS), a pioneer in RNA-targeted medicines, develops therapies for neurological, cardiovascular, and rare diseases, including Wainua and Spinraza. Shares recently hovered near $75, with a $12B market cap, after Q4 revenue beat estimates at $203M despite a loss. Positive data on Tryngolza for triglycerides and priority FDA reviews for olezarsen have fueled 126% 1-year gains, though recent volatility led to YTD -5% performance. Sentiment shifts positively on rare disease franchise expansion and partnerships, with upcoming catalysts like Phase 3 readouts enhancing market positioning.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top-performing AI trading bots from its library of hundreds that trade thousands of tickers across diverse strategies, timeframes, and market conditions. Only those excelling in current volatility—such as trend-following in semiconductors or hedging small caps—earn a spot, with stats like annualized returns up to +217%, win rates of 53-95%, and profit factors to 25.8. Examples include a biotech bot at +24% annualized with 95% win rate and multi-sector agents hitting +132% on 25 tickers. These bots vary in style, from 15-minute AI/ML signals to longer holds, offering risk-managed copy trading. Explore Trending AI Robots to align with today’s market dynamics.
Head-to-Head Comparison
ABBV, INCY, and IONS operate in biopharma but diverge in models: ABBV’s diversified portfolio yields stability and dividends, contrasting INCY’s oncology focus with high revenue growth but no yield, and IONS’ innovative RNA platform targeting rare diseases. Growth drivers include ABBV’s immunology momentum, INCY’s Jakafi expansions, and IONS’ approvals. Recent momentum favors IONS (126% 1Y) over INCY (37%) and flat ABBV. Risks encompass competition and patents for all, with ABBV least volatile (beta 0.33). Valuation sensitivity shows ABBV’s attractive forward P/E versus growth peers; sentiment tilts to pipeline catalysts across the board.
Tickeron AI Verdict
Tickeron’s AI currently leans toward IONS based on superior trend consistency from rare disease catalysts and 126% 1-year relative positioning, outweighing short-term volatility. ABBV offers probabilistic stability via dividends and scale, while INCY trails on post-earnings momentum despite revenue strength. Factors like approvals and sector rotations favor IONS for near-term outperformance potential.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s), and IONS’s FA Score reflects 0 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- INCY’s FA Score: 1 green, 4 red.
- IONS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while INCY’s TA Score has 5 bullish TA indicator(s), and IONS’s TA Score reflects 4 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- INCY’s TA Score: 5 bullish, 4 bearish.
- IONS’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while INCY (@Biotechnology) price change was +1.43% , and IONS (@Biotechnology) price fluctuated +0.72% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.75%. For the same industry, the average monthly price growth was +4.38%, and the average quarterly price growth was +7.68%.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +12.41%, and the average quarterly price growth was +11.94%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
INCY is expected to report earnings on Apr 28, 2026.
IONS is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.75% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+6.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | INCY | IONS | |
| Capitalization | 360B | 19.3B | 12.4B |
| EBITDA | 17.6B | 1.76B | -273.12M |
| Gain YTD | -7.305 | -1.873 | -4.298 |
| P/E Ratio | 85.95 | 15.12 | N/A |
| Revenue | 61.2B | 5.14B | 944M |
| Total Cash | N/A | 3.58B | 2.68B |
| Total Debt | 67.5B | 40.4M | 2.07B |
ABBV | INCY | IONS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 69 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 14 | 72 | 62 | |
SMR RATING 1..100 | 1 | 32 | 98 | |
PRICE GROWTH RATING 1..100 | 55 | 47 | 41 | |
P/E GROWTH RATING 1..100 | 40 | 100 | 74 | |
SEASONALITY SCORE 1..100 | n/a | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for INCY (69) in the Biotechnology industry, and is somewhat better than the same rating for IONS (100) in the Biotechnology industry. This means that ABBV's stock grew somewhat faster than INCY’s and somewhat faster than IONS’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (62) in the Biotechnology industry, and is somewhat better than the same rating for INCY (72) in the Biotechnology industry. This means that ABBV's stock grew somewhat faster than IONS’s and somewhat faster than INCY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as INCY (32) in the Biotechnology industry, and is significantly better than the same rating for IONS (98) in the Biotechnology industry. This means that ABBV's stock grew similarly to INCY’s and significantly faster than IONS’s over the last 12 months.
IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as INCY (47) in the Biotechnology industry, and is in the same range as ABBV (55) in the Pharmaceuticals Major industry. This means that IONS's stock grew similarly to INCY’s and similarly to ABBV’s over the last 12 months.
ABBV's P/E Growth Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (74) in the Biotechnology industry, and is somewhat better than the same rating for INCY (100) in the Biotechnology industry. This means that ABBV's stock grew somewhat faster than IONS’s and somewhat faster than INCY’s over the last 12 months.
| ABBV | INCY | IONS | |
|---|---|---|---|
| RSI ODDS (%) | 4 days ago 63% | 4 days ago 63% | 4 days ago 80% |
| Stochastic ODDS (%) | 4 days ago 58% | 4 days ago 57% | 4 days ago 75% |
| Momentum ODDS (%) | 4 days ago 65% | 4 days ago 63% | 4 days ago 70% |
| MACD ODDS (%) | 4 days ago 67% | 4 days ago 67% | 4 days ago 73% |
| TrendWeek ODDS (%) | 4 days ago 58% | 4 days ago 63% | 4 days ago 71% |
| TrendMonth ODDS (%) | 4 days ago 51% | 4 days ago 60% | 4 days ago 74% |
| Advances ODDS (%) | 12 days ago 57% | 12 days ago 61% | 6 days ago 66% |
| Declines ODDS (%) | 8 days ago 48% | 5 days ago 60% | 8 days ago 65% |
| BollingerBands ODDS (%) | 4 days ago 62% | 4 days ago 67% | 4 days ago 67% |
| Aroon ODDS (%) | 4 days ago 43% | 4 days ago 60% | 4 days ago 74% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.29% | ||
| PFE - ABBV | 57% Loosely correlated | +1.25% | ||
| BMY - ABBV | 55% Loosely correlated | +2.05% | ||
| BIIB - ABBV | 51% Loosely correlated | +0.76% | ||
| AMGN - ABBV | 51% Loosely correlated | +1.69% | ||
| NVS - ABBV | 49% Loosely correlated | +1.50% | ||
More | ||||
IONS and
Correlation & Price change
A.I.dvisor indicates that over the last year, IONS has been closely correlated with CYTK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if IONS jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | +0.60% | ||
| CYTK - IONS | 66% Closely correlated | +1.97% | ||
| MLYS - IONS | 66% Loosely correlated | +0.07% | ||
| MNKD - IONS | 49% Loosely correlated | +3.27% | ||
| IDYA - IONS | 47% Loosely correlated | +4.31% | ||
| ARWR - IONS | 46% Loosely correlated | +2.25% | ||
More | ||||